NASDAQ : ZLAB
Zai Lab Limited — Key statistics
Healthcare · Biotechnology · China
Last price 22.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.78B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.69B |
| Enterprise Value | 2.33B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 124.15M |
| Shares Change (YoY) | +6.01% |
| Shares Change (QoQ) | +0.87% |
| Owned by Insiders (%) | 1.97% |
| Owned by Institutions (%) | 65.18% |
| Float | 115.13M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.98 |
| Forward PS | 5.82 |
| PB Ratio | 4.01 |
| P/TBV Ratio | 5.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.13 |
| Quick Ratio | 1.61 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.13 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -26.91% |
| Return on Assets (ROA) | -14.75% |
| Return on Invested Capital (ROIC) | -17.90% |
| Return on Capital Employed (ROCE) | -40.87% |
| Weighted Average Cost of Capital (WACC) | 7.68% |
| Revenue Per Employee | $252,026 |
| Profits Per Employee | -$105,501 |
| Employee Count | 1,784 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 5.67 |
Taxes
| Measure | Value |
|---|
| Income Tax | -2.51M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.72 |
| 52-Week Price Change | -16.65% |
| 50-Day Moving Average | 24.85 |
| 200-Day Moving Average | 20.99 |
| Relative Strength Index (RSI) | 39.12 |
| Average Volume (20 Days) | 1,025,467 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.84M |
| Short Previous Month | 7.15M |
| Short % of Shares Out | 8.00% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.97 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 449.61M |
| Gross Profit | 16.99M |
| Operating Income | -264.10M |
| Pretax Income | -190.72M |
| Net Income | -188.21M |
| EBITDA | -248.17M |
| EBIT | -264.10M |
| Loss Per Share | -$0.17 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 617.52M |
| Total Debt | 254.58M |
| Net Cash | 362.95M |
| Net Cash Per Share | $2.92 |
| Equity (Book Value) | 607.04M |
| Book Value Per Share | 5.41 |
| Working Capital | 485.45M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -133.38M |
| Capital Expenditures | -6.19M |
| Depreciation & Amortization | 15.93M |
| Net Borrowing | 53.38M |
| Free Cash Flow | -139.57M |
| FCF Per Share | -$1.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | 3.78% |
| Operating Margin | -58.74% |
| Pretax Margin | -42.42% |
| Profit Margin | -41.86% |
| EBITDA Margin | -55.20% |
| EBIT Margin | -58.74% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.01% |
| Shareholder Yield | -6.01% |
| Earnings Yield | -0.78% |
| FCF Yield | -5.19% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $33.48 |
| Price Target Difference | 54.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 15.75% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.04 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |